Biophysical characterization of a liposomal formulation of cytarabine and daunorubicin

International Journal of Pharmaceutics

Volumn 391, Issue 1-2, 2010, Pages 248-259

  Dicko, Awa ^a   Kwak, Sungjong ^a   Frazier, April A ^a   Mayer, Lawrence D ^a   Liboiron, Barry D ^a  

^a Celator Pharmaceuticals Corp   (Canada)

Author keywords

Copper gluconate; CPX 351; Cytarabine; Daunorubicin; EPR; Liposomes

Indexed keywords

ANTILEUKEMIC AGENT; BUFFER; CPX 351; CYTARABINE PLUS DAUNORUBICIN; EXCIPIENT; GLUCONATE COPPER; LIPOSOME; TRIETHANOLAMINE; UNCLASSIFIED DRUG;

ARTICLE; BIOPHYSICS; CONTROLLED STUDY; DRUG DELIVERY SYSTEM; DRUG DISPOSITION; DRUG FORMULATION; DRUG POTENTIATION; DRUG RETENTION; ELECTRON SPIN RESONANCE; ENCAPSULATION; FLUORESCENCE SPECTROSCOPY; PHASE TRANSITION; PHYSICAL CHEMISTRY; PRIORITY JOURNAL; ZETA POTENTIAL;

BUFFERS; CHEMISTRY, PHARMACEUTICAL; CYTARABINE; DAUNORUBICIN; ETHANOLAMINES; EXCIPIENTS; GLUCONATES; LIPOSOMES; PARTICLE SIZE; TRANSITION TEMPERATURE;

EID: 77952888216     PISSN: 03785173     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ijpharm.2010.02.014     Document Type: Article

References (36)

1. Abraham S.A., Edwards K., Karlsson G., MacIntosh S., Mayer L.D., McKenzie C., Bally M.B. Formation of transition metal-doxorubicin complexes inside liposomes. Biochim. Biophys. Acta 2002, 1565:41-54.
2. Almgren M., Edwards K., Karlsson G. Cryo transmission electron microscopy of liposomes and related structures. Colloids Surfaces A: Physicochem. Eng. Aspects 2000, 174:3-21.
3. Angeletti C., Nichols J.W. Dithionite quenching rate measurement of the inside-outside membrane bilayer distribution of 7-nitrobenz-2-oxz-1,3-diazol-4-yl-labeled phospholipids. Biochemistry 1998, 37:15114-15119.
4. Batist G., Miller W., Mayer L., Janoff A., Swenson C., Louie A., Chi K., Chia S., Gelmon K. Ratiometric dosing of irinotecan (IRI) and floxuridine (FLOX) in a phase I trial: a new approach for enhancing the activity of combination chemotherapy. J. Clin. Oncol. 2007, 25:109s.
5. Batist G., Gelmon K.A., Chi K.N., Miller W.H., Chia S.K., Mayer L.D., Swenson C.E., Janoff A.S., Louie A.C. Safety, pharmacokinetics, and efficacy of CPX-1 liposome injection in patients with advanced solid tumors. Clin. Cancer Res. 2009, 15:692-700.
6. Bayne W.F., Mayer L.D., Swenson C.E. Pharmacokinetics of CPX-351 (cytarabine/daunorubicin HCl) liposome injection in the mouse. J. Pharm. Sci. 2009, 98:2540-2548.
7. Berger N.A., Eichhorn G.L. Interaction of metal ions with polynucleotides and related compounds XIV: nuclear magnetic resonance studies of the binding of copper(II) to adenine nucleotides. Biochemistry 1971, 10:1847-1857.
8. Boman N.L., Masin D., Mayer L.D., Cullis P.R., Bally M.B. Liposomal vincristine which exhibits increased drug retention and increased circulation longevity cures mice bearing P388 tumors. Cancer Res. 1994, 54:2830-2833.
9. Carithers R.P., Palmer G. Characterization of the potentiometric behavior of soluble cytochrome oxidase by magnetic circular dichroism: evidence in support of heme-heme interaction. J. Biol. Chem. 1981, 256:7967-7976.
10. Phospholipids Handbook 1993, Marcel Dekker, New York. G. Cevc (Ed.).
11. Chao Y.H., Kearns D.R. Magnetic resonance studies of copper(II) interaction with nucleosides and nucleotides. J. Am. Chem. Soc. 1977, 99:6425-6434.
12. Cullis P.R., Hope M.J., Bally M.B., Madden T.D., Mayer L.D., Fenske D.B. Influence of pH gradients on the transbilayer transport of drugs, lipids, peptides and metal ions into large unilamellar vesicles. Biochim. Biophys. Acta. 1997, 1331:187-211.
13. Dicko A., Frazier A.A., Liboiron B.D., Hinderliter A., Ellena J.F., Xie X., Cho C., Weber T., Tardi P.G., Cabral-Lilly D., Cafiso D.S., Mayer L.D. Intra and inter-molecular interactions dictate the aggregation state of irinotecan co-encapsulated with floxuridine inside liposomes. Pharm. Res. 2008, 25:1702-1713.
14. Dicko A., Tardi P., Xie X., Mayer L. Role of copper gluconate/triethanolamine in irinotecan encapsulation inside the liposomes. Int. J. Pharm. 2007, 337:219-228.
15. Escandar G.M., Sala L.F. Complexes of Cu(II) with d-aldonic and d-alduronic acids in aqueous solution. Can. J. Chem. 1992, 70:2053-2057.
16. Greenaway F.T., Dabrowiack J.C. The binding of copper ions to daunomycin and adriamycin. J. Inorg. Biochem. 1982, 16:91-107.
17. Haran G., Cohen L.K., Bar L.K., Barenholz Y. Transmembrane ammonium sulfate gradients in liposomes produce efficient and stable entrapment of amphiphatic weak bases. Biochim. Biophys. Acta 1993, 1151:201-215.
18. Harasym T.O., Tardi P.G., Harasym N.L., Harvie P., Johnstone S., Mayer L.D. Increased preclinical efficacy of irinotecan and floxuridine co-encapsulated inside liposomes is associated with tumor delivery of synergistic drug ratios. Oncol. Res. 2007, 16:361-374.
19. Harasym T.O., Tardi P.G., Johnstone S.A., Mayer L.D., Bally M.B., Janoff A.S. Fixed drug ratio liposomes formulations of combination cancer therapeutics. Liposome Technology 2007, 25-48. CRC Press, Boca Raton, FL. 3rd ed. G. Gregoriadis (Ed.).
20. Kas J., Sackmann E. Shape transitions and shape stability of giant phospholipid vesicles in pure water induced by area-to-volume changes. Biophys. J. 1991, 60:825-844.
21. Lasic D.D., Ceh B., Stuart M.C., Guo L., Frederik P.M., Barenholz Y. Transmembrane gradient driven phase transitions within vesicles: lessons for drug delivery. Biochim. Biophys. Acta 1995, 1239:145-156.
22. Lasic D.D., Frederik P.M., Stuart M.C., Barenholz Y., McIntosh T.J. Gelation of liposome interior: a novel method for drug encapsulation. FEBS Lett. 1992, 312:255-258.
23. Li X., Hirsh D.J., Cabral-Lilly D., Zirket A., Gruner S.M., Janoff A.S., Perkins W.R. Doxorubicin physical state in solution and inside liposomes loaded via a pH gradient. Biochim. Biophys. Acta 1998, 1415:23-40.
24. May P.M., Williams G.K., Williams D.R. Speciation studies of adriamycin, quelamycin and their metal-complexes. Inorg. Chim. Acta 1985, 46:221-228.
25. Mayer L.D., Harasym T.O., Tardi P.G., Harasym N.L., Shew C.R., Johnstone S.A., Ramsay E.C., Bally M.B., Janoff A.S. Ratiometric dosing of anticancer drug combinations: controlling drug ratios after systemic administration dictates therapeutic activity in tumor-bearing mice. Mol. Cancer Ther. 2006, 5:1854-1863.
26. Mayer L.D., Janoff A.S. Optimizing combination chemotherapy by controlling drug ratios. Mol. Interv. 2007, 7:216-223.
27. McElhaney R.N. The use of differential scanning calorimetry and differential thermal analysis in studies of model and biological membranes. Chem. Phys. Lipids 1982, 30:229-259.
28. McIntyre J.C., Sleight R.G. Fluorescence assay for phospholipid membrane asymmetry. Biochemistry 1991, 30:11819-11827.
29. Mui B.L-S., Döbereiner H.-G., Madden T.D., Cullis P.R. Influence of transbilayer area asymmetry on the morphology of large unilamellar vesicles. Biophys. J. 1995, 39:930-941.
30. Park J.W. Liposome-based drug delivery in breast cancer treatment. Breast Cancer Res. 2002, 4:95-99.
31. Perkins W.R., Minchey S.R., Ahl P.L., Janoff A.S. The determination of liposome captured volume. Chem. Phys. Lipids 1993, 64:197-217.
32. Pecsok R.L., Juvet R.S. The gluconate complexes. I. Copper gluconate complexes in strongly basic media. J. Am. Chem. Soc. 1955, 77:202-206.
33. Sengupta S., Eavarone D., Capila I., Zhao G., Watson N., Kiziltepe T., Sasisekharan R. Temporal targeting of tumor cells and neavasculature with a nanoscale delivery system. Nature 2005, 436:568-572.
34. Tardi P.G., Gallagher R.C., Johnstone S., Harasym N., Webb M., Bally M.B., Mayer L.D. Coencapsulation of irinotecan and floxuridine into low cholesterol-containing liposomes that coordinate drug release in vivo. Biochim. Biophys. Acta 2007, 1768:678-687.
35. Tardi P.G., Dos Santos N., Harasym T.O., Johnstone S.A., Zisman N., Tsang A.W., Bermudes D.G., Mayer L.D. Drug ratio-dependent antitumor activity of irinotecan and cisplatin combinations in vitro and in vivo. Mol. Cancer Ther. 2009, 8:2266-2275.
36. Tardi P., Johnstone S., Harasym N., Xie S., Harasym T., Zisman N., Harvie P., Bermudes D., Mayer L. In vivo maintenance of synergistic cytarabine: daunorubicin ratios greatly enhances therapeutic efficacy. Leuk. Res. 2009, 1:129-139.